|
Characteristics
|
TCZ users (N= 46)
|
TNFi users (N= 47)
|
|---|
|
Age (years)
|
60 (28 to 75)
|
55 (30 to 76)
|
|
Gender
|
3 males, 43 females
|
9 males, 38 females
|
|
Hb (g/dl)
|
11.4 (8.9 to 14.4)
|
11.8 (7.7 to 15.3)
|
|
MCV (fl)
|
91.7 (72.4 to 101.5)
|
94.2 (79.3 to 104.1)
|
|
Ferritin (ng/ml)
|
81.4 (13.5 to 285.3)
|
99.2 (9.8 to 398.2)
|
|
Fe (μg/dl)
|
45.8 (9.0 to 120.0)
|
56.5 (10.0 to 138.0)
|
|
CRP (mg/dl)
|
3.37 (0.05 to 15.24)
|
2.11 (0.04 to 9.16)
|
|
Hepcidin-25 (ng/ml)
|
28.6 (0.3 to 123)
|
30.5 (0.4 to 127.4)
|
|
Duration of RA (years)
|
12.54 (1.6 to 43)
|
8.16 (0.8 to 28)
|
|
SJC
|
7.24 (0 to 24)
|
5.59 (0 to 23)
|
|
TJC
|
6.74 (0 to 23)
|
6.54 (1 to 23)
|
|
RF (IU/ml)
|
165.54 (0 to 1,166)
|
144.24 (0 to 1,625)
|
|
DAS28
|
4.74 (2.00to 7.39)
|
4.45 (2.33 to 7.23)
|
- aCRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; Fe, serum iron; ferritin, serum ferritin; Hb, hemoglobin; MCV, mean corpuscular volume; RF, rheumatoid factor; SJC, swollen joint count; TCZ, tocilizumab; TJC, tender joint count; TNFi, tumor necrosis factor α inhibitor. All data are means (ranges) unless otherwise specified.
